Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CKP > CTLA-4 > CT4-H82F3

Biotinylated Human CTLA-4 Protein, Fc,Avitag™

Recommended Hot Products:
Based on the high binding affinity between biotin-streptavidin systems, our Streptavidin series products are recommended to use together with biotinylated proteins to get lower non-specific binding results in a shorter time.
  • Synonym
    CTLA4,CD152
  • Source
    Biotinylated Human CTLA-4, Fc,Avitag (CT4-H82F3) is expressed from human 293 cells (HEK293). It contains AA Ala 37 - Phe 162 (Accession # P16410-1).
    Predicted N-terminus: Ala 37
  • Molecular Characterization
    Online(Ala 37 - Phe 162) P16410-1

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 41.8 kDa. The protein migrates as 48-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Biotinylation
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Biotin:Protein Ratio
    Passed as determined by the HABA assay / binding ELISA.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) SDS-PAGE gel

Biotinylated Human CTLA-4, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Biotinylated Human CTLA-4, Fc,AvitagBiotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) ELISA bioactivity

Immobilized Human B7-2, Fc Tag (Cat. No. CD6-H5257) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) with a linear range of 0.6-10 ng/mL (QC tested).

Biotinylated Human CTLA-4, Fc,AvitagBiotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) ELISA bioactivity

Immobilized Human B7-1, Fc Tag (Cat. No. B71-H5259) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) with a linear range of 0.6-10 ng/mL (Routinely tested).

Biotinylated Human CTLA-4, Fc,AvitagBiotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) ELISA bioactivity

Immobilized Cynomolgus / Rhesus macaque B7-2, His Tag (Cat. No. CD6-C52H5) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) with a linear range of 0.02-0.625 μg/mL (Routinely tested).

Biotinylated Human CTLA-4, Fc,AvitagBiotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) ELISA bioactivity

Immobilized Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Ipilimumab with a linear range of 0.2-2 ng/mL (Routinely tested).

Biotinylated Human CTLA-4, Fc,AvitagBiotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) ELISA bioactivity

Serial dilutions of Ipilimumab neutralizing antibody (1:2 serial dilutions, from 40 μg/mL to 0.019 μg/mL) were added into Human B7-1, Fc Tag (Cat. No. B71-H5259): Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points before curve fitting.

Biotinylated Human CTLA-4, Fc,AvitagBiotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) ELISA bioactivity

Serial dilutions of Ipilimumab neutralizing antibody (1:2 serial dilutions, from 40 μg/mL to 0.019 μg/mL) were added into Human B7-2, Fc Tag (Cat. No. CD6-H5257): Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points before curve fitting.

  • Citations
  • Background
    CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $250.00

Price(USD) : $1080.00

Price(USD) : $30.00

Price(USD) : $130.00

Price(USD) : $210.00

Price(USD) : $210.00

Price(USD) : $350.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:48 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message